Cambridge Heart Releases Preliminary Fourth Quarter Revenue Results; Announcement Made in Conjunction with Presentation at Gargiulo Healthcare Conference.

Business/Technology Editors and Health/Medical Writers

BEDFORD, Mass.--(BW HealthWire)--Jan. 31, 2001

Cambridge Heart, Inc. (NASDAQ:CAMH) will be presenting at the Gargiulo Healthcare Conference in New York City today at 11:00 am. As part of their presentation, Jeffrey Arnold, Chairman and CEO and David Chazanovitz, President & COO will discuss the progress the Company has made in 2000, as well as, plans for 2001.

In conjunction with the Gargiulo Conference, which precedes Cambridge Hearts' earnings release date, the Company is releasing preliminary revenue results for the fourth quarter and fiscal year ended December 31, 2000. Complete financial results for the quarter will be reported on February 7, 2001 followed by a conference call with management.

For the quarter and fiscal year ended December 31, 2000, the Company estimates that revenue will be slightly in excess of $600,000 and $1,900,000 respectively.

"We are very encouraged with the strong fourth quarter," stated Mr. Chazanovitz. "We had predicted that the introduction of the Heartwave system would show up in revenue growth starting in the fourth quarter. In fact, Q4 revenue was approximately 40% higher than both Q3 and the average revenue for the previous three quarters of 2000. We believe this supports our contention that we are at an inflection point in financial performance that will become increasingly evident as we expand our distribution and marketing efforts."

Commenting on the Company's progress in 2000, Mr. Arnold stated, "We are now ready to capitalize on our investments and penetrate the substantial market for our products. We have introduced the Heartwave product, key partnerships are in place and we have experienced significant success in obtaining reimbursement for the Alternans Test. In addition, two major studies on Alternans have been published recently in The Lancet in August 2000 and the Journal of the American College of Cardiology in December."

Mr. Chazanovitz summarized the talk by stating, "Cambridge Heart's Microvolt T-wave Alternans represents a significant opportunity with a proven technology. Building off of a strong fourth quarter performance, the pieces are in place to make 2001 a successful year."

The Company will hold its quarterly earnings conference call on Wednesday, February 7, 2001 at 4:15 p.m. The call in number is 800-231-9012 within the U.S. or 719-457-2617 outside the U.S. A recording of the call will be available for 48 hours after its conclusion by dialing 888-203-1112 within the U.S. or 719-457-0820 outside the U.S. The reservation number is 469776. This playback will begin approximately two hours following the call. Webcast will be available at www.cambridgeheart.com.

About the Cambridge Heart Microvolt Alternans Test

The Cambridge Heart Microvolt T-wave Alternans Test measures extremely subtle beat-to-beat fluctuations in a person's heartbeat called microvolt T-wave alternans. These tiny heartbeat variations - measured at one millionth of a volt - are detected using proprietary Alternans Sensors while the heart rate is elevated by exercise, use of pharmacological agents or pacing. Extensive clinical research has shown that patients with symptoms of or at risk for life threatening arrhythmias who test positive for T-wave alternans using Cambridge Heart technology are at significant risk for subsequent sudden cardiac events including sudden death. Cambridge Heart's Microvolt Alternans Test is the only noninvasive test cleared by FDA to identify patients at risk for sudden cardiac death.

About Cambridge Heart, Inc.

Cambridge Heart is engaged in the research, development and commercialization of products for the non-invasive diagnosis of cardiac disease. Using innovative technologies, the Company is addressing such key problems in cardiac diagnosis as the identification of those at risk of sudden cardiac arrest, the early detection of coronary artery disease, and the prompt and accurate diagnosis of heart attack. The Company, started in 1992, is based in Bedford, Mass., and is traded on the NASDAQ/NMS under the symbol CAMH. Cambridge Heart can be found on the World Wide Web at www.cambridgeheart.com.

Statements made in this press release that are not historical facts include forward-looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those indicated by such forward-looking statements include uncertainties associated with regulatory approval processes, market acceptance, availability of reimbursement and other factors that are included in Cambridge Heart's Annual Report on Form 10-K for the year ending December 31,1999.